NRX Pharmaceuticals (NRXP) AI Stock Analysis

• Market Cap: $62.61M
• Dividend Yield: N/A
• Average Volume (3M): 246.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: N/A
• EPS Growth: 41.01%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 19,503,412
• 10 Day Avg. Volume: 128,580
• 30 Day Avg. Volume: 246,153
• PEG Ratio: -0.13
• Price to Book (P/B): -2.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.28
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 2.30K
• Enterprise Value/Gross Profit: 55.11K
• Enterprise Value/Ebitda: -0.59
• 1Y Price Target: $32.00
• Price Target Upside: 896.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: ―

NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company's financial health if successful.

Positive Factors

Product Development

The ANDA could lead to approval of the only preservative-free form of ketamine, making it a unique product in the market.

Regulatory Progress

FDA waived the $4.3M NDA Submission fee for NRX-101, reducing financial burden on the company.

Strategic Partnerships

Management has indicated significant interactions with developers of TMS equipment, suggesting strong strategic partnerships to offer comprehensive treatment solutions.

Negative Factors

Financial Health

Company's cash and equivalents of $5.5M are expected to support operations through 2025 and the potential approvals of NRX-100 and NRX-101.

NRX Pharmaceuticals Business Overview & Revenue Model

Company Description

NRX Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of central nervous system disorders and other critical health conditions. The company operates in the healthcare sector with a particular emphasis on drug development for serious mental illnesses, respiratory diseases, and other critical care indications. Its core products include investigational drugs designed to offer new treatment options for patients with severe mental health disorders and life-threatening pulmonary diseases.

How the Company Makes Money

NRX Pharmaceuticals makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue streams include partnerships with other pharmaceutical companies for drug development and distribution, as well as potential sales from its proprietary drugs once they receive regulatory approval. Additionally, NRX Pharmaceuticals may engage in licensing agreements, where they receive upfront payments, milestone payments, and royalties based on the sales performance of their licensed products. The company's earnings are also influenced by its ability to secure funding through investments, grants, or collaborations geared towards advancing its research and development efforts.

NRX Pharmaceuticals Financial Statement Overview

Summary

NRX Pharmaceuticals faces significant financial challenges, with ongoing net losses and negative equity. Despite typical early-stage biotech challenges, the company must improve revenue generation and manage cash flow better.

Income Statement

NRX Pharmaceuticals shows consistent net losses and zero revenue over the years, leading to negative EBIT and EBITDA margins. There is no revenue growth, which is typical for early-stage biotech firms focusing on R&D and product development. The company faces challenges in transitioning from R&D to revenue generation.

Balance Sheet

The balance sheet reveals negative stockholders' equity and high liabilities compared to assets, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, suggesting high financial risk. However, the absence of debt in the latest report is a slight positive aspect.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn without incoming revenue. The free cash flow is also negative, indicating the company relies on financing activities for liquidity. This cash flow scenario is common in biotech companies at the research stage.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-5.00K	-4.00K	-2.00K	-907.00K
EBITDA	-18.50M	-30.02M	-39.75M	-93.04M	-51.72M
Net Income	-25.13M	-30.15M	-39.75M	-93.06M	-51.78M
Balance Sheet
Total Assets	3.65M	7.32M	25.82M	32.73M	2.94M
Cash, Cash Equivalents and Short-Term Investments	1.44M	4.59M	20.05M	27.61M	1.86M
Total Debt	6.58M	9.16M	10.53M	518.00K	797.00K
Total Liabilities	26.87M	19.05M	18.41M	11.92M	46.71M
Stockholders Equity	-23.22M	-11.73M	7.41M	20.81M	-43.77M
Cash Flow
Free Cash Flow	-10.64M	-21.66M	-39.77M	-37.71M	-2.27M
Operating Cash Flow	-10.64M	-21.66M	-39.76M	-37.70M	-2.27M
Investing Cash Flow	0.00	-3.00K	-10.00K	-7.00K	-2.00K
Financing Cash Flow	7.49M	6.20M	32.21M	63.46M	3.25M

NRX Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXP, the sentiment is Neutral. The current price of 3.21 is below the 20-day moving average (MA) of 3.31, above the 50-day MA of 2.88, and above the 200-day MA of 2.24, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 33.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRXP.

NRX Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	56 Neutral	$62.72M	―	1063.61%	―	475.53%	89.94%
Sector *	52 Neutral	$7.52B	0.21	-63.76%	2.30%	16.15%	0.89%
RNXT	49 Neutral	$47.00M	―	-136.13%	―	―	61.43%
NRXP	45 Neutral	$62.61M	―	108.28%	―	―	41.01%
RVPH	28 Underperform	$26.60M	―	-916.17%	―	―	45.15%

NRX Pharmaceuticals Corporate Events

NRX Pharmaceuticals Reports 2024 Financial Results and Strategy

NRx Pharmaceuticals announced its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its drug development and corporate strategy. The company initiated the filing of a New Drug Application for NRX-100 for suicidal depression and plans to file for NRX-101 for bipolar depression. Additionally, NRx Pharmaceuticals is negotiating licensing agreements for NRX-100 and pursuing acquisitions to establish a national network of interventional psychiatry centers. These efforts aim to strengthen the company’s position in the mental health treatment market and potentially increase its profitability by the end of 2025.